This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of lymphoma subtypes.

Lymphoma includes:





Details the most current management across the spectrum of lymphoma subtypes
Expert contributors from across the US and Canada
Multidisciplinary coverage and emphasis on emerging therapeutic options, cutting edge developments and clinical research with near-term potential in clinical management

Series Description:

Emerging Cancer Therapeutics is an invited review publication providing a thorough analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence; current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the speciality, as well as on quality and outcomes analysis. Published three times a year, Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and haematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.

Series edited by: Jame Abraham